Critical Survey: Monte Rosa Therapeutics (GLUE) vs. Its Rivals

Monte Rosa Therapeutics (NASDAQ:GLUE) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Monte Rosa Therapeutics to related businesses based on the strength of its dividends, profitability, risk, earnings, institutional ownership, valuation and analyst recommendations.

Valuation & Earnings

This table compares Monte Rosa Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Monte Rosa Therapeutics	$70.33 million	-$38.63 million	-6.65
Monte Rosa Therapeutics Competitors	$756.44 million	$13.58 million	-18.85

Monte Rosa Therapeutics’ peers have higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Monte Rosa Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1	2	8	1	2.75
Monte Rosa Therapeutics Competitors	9869	15284	45613	1598	2.54

Monte Rosa Therapeutics currently has a consensus price target of $26.44, suggesting a potential upside of 184.04%. As a group, “Biotechnology” companies have a potential upside of 124.54%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than its peers.

Volatility and Risk

Monte Rosa Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics’ peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Institutional and Insider Ownership

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Monte Rosa Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-186.24%	-30.14%	-20.35%
Monte Rosa Therapeutics Competitors	-12,323.33%	-195.38%	-30.39%

Summary

Monte Rosa Therapeutics beats its peers on 10 of the 13 factors compared.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.